- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04679844
Estudio posterior a la comercialización de la masilla MagnetOs en comparación con el autoinjerto en pacientes sometidos a fusión lumbar posterolateral (PROOF)
Un estudio prospectivo, aleatorizado, de un solo centro para evaluar la seguridad y el rendimiento de la masilla MagnetOs en comparación con el autoinjerto en pacientes sometidos a fusión posterolateral lumbar/toracolumbar (PLF) instrumentada en dos niveles
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
Descripción general del estudio
Estado
Descripción detallada
In this study, following a screening period of a maximum of 30 days, 60 patients will undergo up to two-level instrumented posterolateral fusion (PLF) procedure. Prior to surgery, each patient will be randomized to receive MagnetOs Easypack Putty standalone on the assigned side of the spine and Demineralized Bone Matrix or Fibers mixed with local autograft bone on the other at the diseased levels. They will be followed up at discharge, Week 2, Month 3, Month 6, and Month 12. An interim analysis will be performed once 30 patients have completed their Month 6 visit and have measurements for the endpoints available to measure effectiveness. The primary endpoint will be analyzed at Month 12.
In this study, MagnetOs Easypack Putty will be applied according to the latest Instructions for Use approved in the United States. Specifically, MagnetOs Easypack Putty will be used standalone in patients up to two-level degenerative disc disease with segmental mechanical spinal instability requiring treatment with an instrumented posterolateral spine fusion procedure. The fusion procedure (PLF) will be left to the surgeon's discretion.
Radiographs will be obtained at Screening, Discharge, Month 3, Month 6 and Month 12. CT scans will only be obtained at Month 6 and Month 12.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Irvine, California, Estados Unidos, 92697
- The Regents of the University of California- Irvine Campus
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63130
- The Washington University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Rothman Orthopaedic Institute
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37209
- Tennessee Orthopaedic Alliance
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- University of Washington
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
- Male or female patient ≥ 18 years old.
- Patients with segmental mechanical spinal instability requiring arthrodesis surgery.
Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:
-
instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
-
decreased disc height by > 2 mm, but dependent upon the spinal level
-
Grade II or more listhesis
-
TLICS equal or greater than 5
-
Unstable burst fracture
- Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.
Exclusion Criteria:
- Requires > two-level fusion or expected to need secondary intervention within one year following surgery.
- Had prior PLF fusion or attempted PLF fusion at the involved levels.
- Had previous decompression at the involved levels.
- Women who are or intend to become pregnant within the next 12 months.
- To treat conditions in which general bone grafting is not advisable.
- In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
- In case of significant vascular impairment proximal to the graft site.
- In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage >4 renal disease or Paget's Disease) that affect bone or wound healing.
- In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
- When intraoperative soft tissue coverage is not planned or possible.
- Receiving treatment with medication interfering with calcium metabolism.
- Has degenerative disc disease (DDD) related to a benign or malignant tumor.
- Has history or presence of active malignancy.
- Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
- Is involved in active litigation relating to his/her spinal condition.
- Has participated in an investigational study within 30 days prior to surgery for study devices.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: MagnetOs Easypack Putty
Interventions
|
MagnetOs Easypack Putty used standalone in instrumented posterolateral fusion, 5cc-15c per spine level at the randomized assigned side. |
|
Comparador activo: Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed with local autograft bone
Interventions
|
Demineralized Bone Matrix or Fibers (DBX or Grafton) mixed in a 1:1 vol% with local autologous bone graft used in instrumented posterolateral fusion, 5cc-15cc per level mixed with bone marrow aspirate/blood per spine level at the contralateral side. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Radiographic Fusion by CT Scan
Periodo de tiempo: Month 12
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 12. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes. |
Month 12
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Radiographic Fusion by Plain Radiographs
Periodo de tiempo: Month 6, Month 12
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by plain radiographs. |
Month 6, Month 12
|
|
Radiographic Fusion by CT Scan
Periodo de tiempo: Month 6
|
The rate of posterolateral lumbar/thoracolumbar fusion assessed by CT-scan at Month 6. Radiographic as determined by evidence of bridging trabeculae or continuous bony connection between the superior and inferior transverse processes. |
Month 6
|
|
Functional Outcome by Oswestry Disability Index Questionnaire
Periodo de tiempo: Screening, Week 2, Month 3, 6, and 12
|
Functional outcome by the Oswestry Disability Index questionnaire. Patient-completed questionnaire which gives a subjective percentage score of level of function (disability) in activities of daily living in those rehabilitating from low back pain. The lower the percentage the higher the patient's functionality. 0-20% minimal disability, 80-100% significant disability or bedridden. |
Screening, Week 2, Month 3, 6, and 12
|
|
Back and Leg Pain by Visual Analog Pain Scale Questionnaire
Periodo de tiempo: Screening, Week 2, Month 3, 6, and 12
|
Change in back and leg pain using Visual Analog Pain Scale (0-100). Patient-completed questionnaire scoring pain by using 100 mm line. Zero being no pain, 100 is worst pain imaginable. |
Screening, Week 2, Month 3, 6, and 12
|
|
Neurologic Status by Physical Exam
Periodo de tiempo: Screening, Week 2, Month 3, 6, and 12
|
Change in neurologic status by examination to document stable, improved, or deficits in condition. Stable or improved findings for lower extremities, specifically reflexes, muscle strength, sensory, and straight leg raise. |
Screening, Week 2, Month 3, 6, and 12
|
|
Success Rate
Periodo de tiempo: Week 2, Month 3, 6, and 12
|
Number of patients with secondary surgical interventions (SSI's) such as revisions, re-operations, removals, supplemental fixations, or any other procedure that adjusts or removes part of the original implant configuration with or without replacement of the components within 12 months of surgery. |
Week 2, Month 3, 6, and 12
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety Endpoint - number of patients with Adverse Events
Periodo de tiempo: 12 Months
|
The number of patients with Adverse Events from Screening up to Month 12 after surgery. |
12 Months
|
|
Safety Endpoint - number of patients with Serious Adverse Events
Periodo de tiempo: 12 Months
|
The number of patients with Serious Adverse Events from Screening up to Month 12 after surgery |
12 Months
|
|
Safety Endpoint - number of patients with Adverse Device Effects
Periodo de tiempo: 12 Months
|
The number of patients with Adverse Device Effects from Screening up to Month 12 after surgery. |
12 Months
|
|
Safety Endpoint - number of patients with Device Related Complications
Periodo de tiempo: 12 Months
|
The number of patients with any complications considered to device related with 12 months after surgery. |
12 Months
|
|
Health Economic - Duration of Surgery
Periodo de tiempo: 12 Months
|
Duration of surgery in minutes. |
12 Months
|
|
Health Economic - Duration of Hospitalization
Periodo de tiempo: 12 Months
|
Duration of hospital stay in days. |
12 Months
|
|
Health Economic - Return to Work
Periodo de tiempo: 12 Months
|
Time to return to work in days. |
12 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Cesar Silva, MD, Kuros BioSciences B.V.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- MAG-920-023
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .